Research shows complexity of shared decision-making about lung cancer screening
“Patients with multimorbidity and limited life expectancy are often unaware of the risks of lung cancer screening, and clinicians might be hesitant to discuss it, according to a pair of studies published in the Annals of Family Medicine.”
Using cryo-shocked tumor cells to fight lung cancer
“A team of medical researchers at Zhejiang University, in China, has developed a way to use cryo-shocked tumor cells to fight lung cancer. In their study, published in the journal Science Advances, the group used fast liquid nitrogen treatment to modify tumor cells to carry gene-editing tools to fight tumors in mouse models.”
SCLC Incidence Has Declined Overall, Increased Among Women in the US
“New data suggest the overall incidence of small cell lung cancer (SCLC) in the United States has declined from its peak in the 1980s. However, the incidence of SCLC has increased among women, patients are now more likely to be diagnosed with extensive-stage SCLC, and improvements in overall survival (OS) have been “slow and modest,” according to researchers. They reported these findings in Cancer.”
The woman who built a biotech business from an EU science contest
“Andrea Stephany Diaz founded a startup to improve lung-cancer diagnosis after participating in a 2022 European event for young researchers. Andrea Stephany Diaz gushes with enthusiasm when talking about how she created her own biotechnology company two years ago at the age of 24 in a bid to revolutionise the detection of lung cancer.”
Krazati trial shows promise in lung cancer treatment
“PRINCETON – Bristol Myers Squibb (NYSE: NYSE:BMY) today announced that its Phase 3 KRYSTAL-12 study of KRAZATI (adagrasib) met its primary endpoint of progression-free survival (PFS) in treating patients with a specific mutation in advanced non-small cell lung cancer (NSCLC). The trial, which focused on patients with the KRASG12C mutation who had previously undergone treatment, also achieved a key secondary endpoint of overall response rate (ORR).”
Researchers demonstrate technique for identifying single cancer cells in blood for the first time
“A pioneering study led by a Keele scientist has demonstrated how a single cancer cell can be identified in a sample of blood, paving the way for more personalized and targeted treatments for cancer patients.”
Eligibility for and Prevalence of Lung Cancer Screening in the United States in 2022
“The investigators stated, “In this cross-sectional study, expanded USPSTF eligibility criteria were associated with 5,371,908 additional individuals eligible for [lung cancer screening], with relative increases highest for Asian, Black, Hispanic, and female individuals, aligning with the goal of reducing race and ethnic and sex disparities in eligibility…. While approximately 619,054 newly eligible individuals were screened under expanded recommendations, 2022 [lung cancer screening] prevalence remained low (16.4%). Prior BRFSS analyses using 2013 USPSTF criteria reported [lung cancer screening] prevalence rates of 12.8% in 2019 (20 states) … and 21.2% in 2021 (4 states), indicating a similar [lung cancer screening] prevalence rate in 2021 and 2022 (19.6%).””
Wearable Activity Tracker Data Enhance Patient Assessment in Lung Cancer
“This analysis included 119 patients with advanced lung cancer, who were evaluated on 3 facets of physical activity over 14 days of using the amuelink wearable device from Sony: metabolic equivalent tasks, distance walked, and steps taken.”
Novocure Gets Phase III Win in Patients with Brain Metastases from Lung Cancer
“Novocure’s Tumor Treating Fields (TTFields) is an investigational oncology therapy that uses electric fields that act via many different mechanisms to kill cancer cells. According to the company, the late-stage METIS trial met its primary endpoint, showing a statistically significant improvement in time to intracranial progression in adult patients with brain metastases treated with TTFields therapy and supportive care compared to supportive care alone.”
